International Isotopes, Inc.
I-131 Sodium Iodide & Other Radiochemicals
International Isotopes Inc. (OTCQB: INIS) is proud to be the only FDA approved Sodium Iodide I-131 drug product manufactured in the United States…
EasyFill Automated Iodine Capsule System
This patented system allows for the hands-free preparation of iodine capsules, pairing perfectly with our idoine shielding and reducing radiation exposure.
Nuclear Medicine Calibration Standards
We are the North American distributor for LEA sources for control and calibration of equipment in the fields of radiation protection and metrology.
Cobalt Sealed Source Products
Our cobalt products are used by a broad array of companies for radiation treatment of cancer and vascular deformities of the brain. Cobalt sources are also used for container security examinations at our sea ports and borders.
Calibration Sources & Radioactive Standards
We are the North American distributor for LEA sources for control and calibration of equipment in the fields of radiation protection and metrology.
INIS to Distribute Nuclear Shields B.V. Products
INIS is excited to announce that it has entered into a distribution agreement with Nuclear Shields B.V. to distribute their products in the United States.
Nuclear Shields designs and manufactures a wide rage of radiation shielding products for nuclear medicine, radiology, nuclear imaging and nuclear energy. Nuclear Shields is part of the Van Mullekom Group which was founded in The Netherlands in 1978. The company is privately owned and has factories and offices in the USA, Australia and The Netherlands.
Shahe Bagerdjian, President & CEO of INIS commented, “We are really excited to offer Nuclear Shields’ products to our customers. Their shielding solutions combine high quality engineering and eye-catch designs. Their complete portfolio of products are an excellent fit with our own diverse radioisotope offerings.”
International Isotopes, Inc. Announces Fiscal Results for Fiscal Year 2023
- Revenues Increased 10% in the Twelve Months Ended December 31, 2023 versus prior year.
- Revenue of $12.3 million in the Twelve Months Ended December 31, 2023 was the highest in
Company history. - Gross Profit Increased $1.1 million, or 17%, in the Twelve Months Ended December 31, 2023
versus prior year. - Approximately $0.6 million of Net Cash provided by operating activities in the Twelve Months
Ended December 31, 2023, an increase of over $2.0 million versus prior year.
International Isotopes, Inc. to Divest Depleted Uranium Deconversion Assets to American Fuel Resources for $12,500,000 Cash
IDAHO FALLS, IDAHO, February 8,2024. International Isotopes Inc. (OTCQB: INIS) (“International Isotopes,” “INIS” or the “Company”) is pleased to announce that it has entered into a definitive agreement to sell all of its assets related to its depleted uranium deconversion and fluorine processing venture (“DUF6 Assets”) to American Fuel Resources, LLC (“AFR”) for $12,500,000 cash at closing.
International Isotopes, Inc. Announces the Acquisition of the AMICI, Inc. Product Line
The Products Include All Molds, Manufacturing, And Registration Rights To AMICI’s Leading Products, Including The “Swirler”, “UltraShield”, and “Tru-Fit” Mouth Piece.
We are excited to announce that we have acquired the manufacturing molds, device registrations, trademarks, and all production rights to the AMICI Inc. line of nuclear lung ventilation products.
Watch for more news and updates in the coming weeks, and follow us on LinkedIn.